Navigation Links
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Date:1/25/2008

FRAZER, Pa., Jan. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain. In addition, the FDA notified the Company that it will convene an advisory committee panel on May 6, 2008, to consider this application.

"We are pleased that the FENTORA application remains on schedule with an FDA action date of September 13, 2008," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "FENTORA is the first medication that has been evaluated in controlled clinical trials for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Therefore, it is not surprising that the agency decided to convene a panel to consider data on the use of FENTORA beyond the initial indication for breakthrough pain in cancer patients."

Included in the FENTORA sNDA are data from three randomized, placebo- controlled clinical trials and one long-term open-label safety study; including data from opioid-tolerant patients with chronic low back and neuropathic pain. The sNDA provides an evaluation of the onset of pain relief from 10 minutes to two hours, and has information regarding bioequivalence data for two routes of administration.

In 2006, FENTORA and an accompanying Risk Minimization Action Plan (RiskMAP) were approved by the FDA only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. The company developed and maintains a FENTORA RiskMAP to address the appropriate patient selection, dosing and administration of the medication.

About Cephalon, Inc.

Cephalon, Inc. is an international biop
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
(Date:11/21/2014)... Diego, CA (PRWEB) November 20, 2014 ... extended their Sartorius Entris Balance promotion . The ... customers seeking a durable, high accuracy, and easy-to-maintain balance ... made in Germany. It was designed to help customer’s ... affordable and a balance that is very durable. Sartorius ...
(Date:11/21/2014)... The report, "Synthetic Biology Market ... kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning ... - Global Forecast to 2018", analyses and ... and challenges. , Browse 99 market data ... pages and in-depth TOC of the global ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Why did ... makes Albert Einstein so instantly recognizable? Why have they ... mathematician, astronomer and author Hilton Ratcliffe seeks out the ... nothing at all to do with science. In " ... Publishing , November 21, 2014), Ratcliffe puts it plainly: ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... Type III von Willebrand Disease, a serious, hereditary ... bleeding disorder, found in ... Behring today,announced that Iran,s Ministry of Health and Medical Education ... on an exclusive,basis throughout Iran, beginning immediately. Haemate P is ...
... Path for ... New Treatments, WILMINGTON, Del. and ... ) today announced,that they will collaborate to help advance understanding of Alzheimer,s,disease ... cutting-edge brain imaging methods., The new alliance will focus on the ...
... TUSTIN, Calif., Dec. 19 AMDL, Inc., (Amex:,ADL), ... a,developer, manufacturer, and marketer of pharmaceutical, nutraceutical,diagnostic, consumer ... open,its first large-scale JPGreen Health and Personal Care ... by Jade to be converted,into a flagship JPGreen ...
Cached Biology Technology:CSL Behring Expands Into Middle East Market with Haemate(R) P 2CSL Behring Expands Into Middle East Market with Haemate(R) P 3AstraZeneca and Banner Alzheimer's Institute Collaborate to Evaluate New Tool Targeting Alzheimer's Disease 2AstraZeneca and Banner Alzheimer's Institute Collaborate to Evaluate New Tool Targeting Alzheimer's Disease 3AstraZeneca and Banner Alzheimer's Institute Collaborate to Evaluate New Tool Targeting Alzheimer's Disease 4AMDL's First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China 2
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... ORLEANS, LA (2 November 2014)—In support of a bold ... Bill & Melinda Gates Foundation today announced an award ... Malaria Vaccine Initiative (MVI) in building new vaccines that ... help realize the "accelerating to zero" agenda. Such vaccines ... what could be called an "immunological bed net." ...
Breaking Biology News(10 mins):PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... waste from nearby manufacturing plants flowed into the waters ... The harbor, which is contaminated with polychlorinated biphenyls (PCBs) ... Superfund cleanup sites. It,s also the site of ... Institution (WHOI) and their colleagues have been working to ...
... The rapid conversion of natural lands to cement-dominated urban centers ... new study involving 147 cities worldwide, surprisingly high numbers of ... environments to the tune of hundreds of bird species ... Contrary to conventional wisdom that cities are a wasteland for ...
... bags, an abundant source of litter on land and ... and other useful petroleum products, researchers report. The ... results in transportation fuels diesel, for example ... biodiesels. Other products, such as natural gas, naphtha (a ...
Cached Biology News:Solving an evolutionary puzzle 2Solving an evolutionary puzzle 3Solving an evolutionary puzzle 4Cities support more native biodiversity than previously thought 2Cities support more native biodiversity than previously thought 3Plastic shopping bags make a fine diesel fuel, researchers report 2
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
... The Experion HighSens analysis kit for 25 ... to perform high-sensitivity RNA analysis (at picogram ... This kit includes 25 RNA HighSens microfluidic ... 2 x 20 microliters RNA HighSens stain, ...
Biology Products: